0001640455-20-000116.txt : 20200916 0001640455-20-000116.hdr.sgml : 20200916 20200916184343 ACCESSION NUMBER: 0001640455-20-000116 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200915 FILED AS OF DATE: 20200916 DATE AS OF CHANGE: 20200916 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duncan Barbara Gayle CENTRAL INDEX KEY: 0001353128 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 201179704 MAIL ADDRESS: STREET 1: C/O INTERCEPT PHARMACEUTICALS, INC. STREET 2: 18 DESBROSSES STREET CITY: NEW YORK STATE: NY ZIP: 10013 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 454870634 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 wf-form4_160029620899164.xml FORM 4 X0306 4 2020-09-15 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001353128 Duncan Barbara Gayle C/O JOUNCE THERAPEUTICS, INC. 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2020-09-15 4 M 0 10000 4.21 A 10000 D Common Stock 2020-09-15 4 S 0 5000 9.50 D 5000 D Common Stock 2020-09-15 4 S 0 5000 10.50 D 0 D Stock Option (Right to Buy) 4.21 2020-09-15 4 M 0 10000 0 D 2026-05-09 Common Stock 10000.0 34271 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 20, 2019. The Reporting Person exercised no discretion with respect to these transactions. The option shares vested and became exercisable in 16 quarterly installments from May 10, 2016. /s/ Kim C. Drapkin, Attorney-in-Fact 2020-09-16